NCT06795815 The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
| NCT ID | NCT06795815 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Condition | Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2025-06-30 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation. The GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life. The "Onco-hema Go wish-ACP" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \> 3 months. In terms of secondary objectives, the study aims to. * Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention * Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs). * To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years age; diagnosed with refractory lymphomas, or leukemia or multiple myeloma or advanced solid tumors and estimated prognosis \> 3 months; * able to communicate in Italian and * to give written consent to the study. Exclusion Criteria: * Patients with severe cognitive impairment or serious psychiatric condition; * refusal to participate to the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06795815 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06795815 currently recruiting?
Yes, NCT06795815 is actively recruiting participants. Contact the research team at marta.perin@ausl.re.it for enrollment information.
Where is the NCT06795815 trial being conducted?
This trial is being conducted at Reggio Emilia, Italy.
Who is sponsoring the NCT06795815 clinical trial?
NCT06795815 is sponsored by Azienda USL Reggio Emilia - IRCCS. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.